Trial Profile
A PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs OTL-103 (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Lenograstim; Plerixafor; Rituximab
- Indications Wiskott-Aldrich syndrome
- Focus Adverse reactions; First in man; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms TIGET-WAS
- Sponsors GlaxoSmithKline; GSK; Orchard Therapeutics
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 02 Feb 2023 Planned End Date changed from 11 Sep 2025 to 11 Sep 2030.
- 10 Dec 2019 Updated results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology